Balance Sheet

Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Apyx Medical (APYX) Other financing activities (2016 - 2025)

Apyx Medical filings provide 11 years of Other financing activities readings, the most recent being $30000.0 for Q2 2025.

On a quarterly basis, Other financing activities changed N/A to $30000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was $60000.0, a 445.45% increase, with the full-year FY2025 number at $60000.0, up 445.45% from a year prior.
Other financing activities hit $30000.0 in Q2 2025 for Apyx Medical, roughly flat from $30000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $1.8 million in Q1 2023 to a low of -$1.6 million in Q3 2023.
Median Other financing activities over the past 3 years was $30000.0 (2025), compared with a mean of $43600.0.